CanSino Biologics (HKG:6185) recorded a net profit attributable to shareholders of 3.0 million yuan for the third quarter of 2024 while the Earnings per share stood at 0.01 yuan for the reporting period, a Tuesday filing with the Hong Kong Exchange said.
The vaccine company's operating revenue for the three months ended Sept. 30 was 263.6 million yuan, 76.09% higher than a year ago.
The company's shares were down nearly 2% on Tuesday's close.
Price (HKD): $26.20, Change: $-0.45, Percent Change: -1.69%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。